Try our beta test site

Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01475461
First received: September 15, 2011
Last updated: December 6, 2016
Last verified: December 2016

September 15, 2011
December 6, 2016
November 2011
January 2013   (Final data collection date for primary outcome measure)
Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 [ Time Frame: Baseline (Day 1), Week 12 ]
HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as less than (<) 6.5 percent (%) by the study-specific central laboratory used. Change from baseline in percentage of HbA1c in participants were reported.
HbA1C - change from baseline [ Time Frame: 84-days ]
Complete list of historical versions of study NCT01475461 on ClinicalTrials.gov Archive Site
  • Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4 and 8 [ Time Frame: Baseline(Day 1), Week 2, 4, 8 ]
    HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as <6.5 percent by the study-specific central laboratory used. Change from baseline in percentage of HbA1c in participants were reported.
  • Change From Baseline in Fasting Plasma Glucose at Week 1, 2, 4, 8, 12 and 14 [ Time Frame: Baseline (Day 1), Week 1, 2, 4, 8, 12, 14 ]
  • Percentage of Participants Achieving Less Than 6.5 Percent and Less Than 7 Percent Glycosylated Hemoglobin (HbA1c) Levels at Week 12 [ Time Frame: Week 12 ]
    HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as <6.5 percent by the study-specific central laboratory used and data are presented in categories of <6.5 percent and <7 percent.
  • Number of Participants With Increase From Baseline Electrocardiogram (ECG)Data [ Time Frame: Baseline (Day 1) up to Week 14 ]
    Criteria for increase from baseline data: PR interval (percent change of greater than or equal to [>=] 25/50% [if baseline>200 then percent change of >25% counts; if baseline <=200 then percent change of >50% counts]; QRS complex (percent change of >=50%); QT Fridericia's correction (QTcF) interval (change of >=30 to <60 millisecond [msec], and change of >=60 msec).
  • Number of Participants With Increase/Decrease From Baseline Vital Signs Data [ Time Frame: Baseline (Day 1) up to Week 14 ]
    Participants who met the criteria for increase or decrease in vital signs data were reported. Criteria for increase or decrease from baseline vital signs data: sitting systolic blood pressure (BP) of >=30 millimeter of mercury (mmHg); sitting diastolic BP of >=20 mmHg and pulse rate was based on investigator's discretion.
  • Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) [ Time Frame: Baseline (Day 1) up to 14 days after last dose (up to 101 days) ]
    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 14 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
  • Percentage of Participants With at Least 1 Hypoglycemic Events (HAE) Episode [ Time Frame: Baseline (Day 1) up to Week 14 ]
    A hypoglycemic event (HAE) was identified by characteristic symptoms or blood glucose levels. HAE is defined as 1 of the given definitions: Characteristic symptoms of HAE with no home glucose monitoring performed where clinical picture included prompt resolution with food intake, subcutaneous glucagon, or intravenous glucose; or characteristic symptoms of HAE with home glucose monitoring measurement =< 70 milligram per deciliter (mg/dL) using ACCU-CHEK plasma-referenced home glucometers or =<74 mg/dL using International Federation of Clinical Chemistry (IFCC) referenced ACCU-CHEK or central laboratory glucometers; or any laboratory glucose value, meeting the following criterion with or without accompanying symptoms: =<49 mg/dL using ACCU-CHEK plasma-referenced home glucometers or =<53 mg/dL using IFCC referenced ACCU-CHEK or central laboratory glucometers.
  • Number of Hypoglycemic Events (HAE) Episodes Per Participant [ Time Frame: Baseline (Day 1) up to Week 14 ]
    A hypoglycemic event (HAE) was identified by characteristic symptoms or blood glucose levels. Median number of events per participant was reported
  • Change From Baseline in Body Weight at Week 2, 4, 8, 12 and 14 [ Time Frame: Baseline (Day 1), Week 2, 4, 8 , 12 , 14 ]
  • Number of Participants With Abnormal Laboratory Values [ Time Frame: Baseline (Day 1) up to Week 14 ]
    Hemoglobin,hematocrit,red blood cells(RBC) count:less than [<]0.8*lower limit of normal[LLN],platelets:<0.5*LLN/greater than [>]1.75*upper limit of normal [ULN],white blood cells(WBC):<0.6*LLN or >1.5*ULN,lymphocytes,total neutrophils:<0.8*LLN or >1.2*ULN, basophils,eosinophil,monocytes:>1.2*ULN;aspartate aminotransferase,alanine aminotransferase, alkaline phosphatase:>0.3*ULN,total protein,albumin:<0.8*LLN or >1.2*ULN;total bilirubin,direct bilirubin,indirect bilirubin:>1.5*ULN;triglycerides,cholesterol:>1.3*ULN, HDL:<0.8*LLN, LDL:>1.2*ULN,blood urea nitrogen,creatinine:>1.3*ULN,uric acid:>1.2*ULN;sodium: <0.95*LLN or >1.05*ULN,potassium,chloride,calcium,bicarbonate:<0.9*LLN or >1.1*ULN;creatine kinase:>2.0*ULN;glucose:<0.6*LLN or >1.5*ULN,urine WBC and RBC:>= 20/High Power Field [HPF]),urine epithelial cells (>=1 HPF),urine bacteria >20 high-powered field;qualitative urine glucose,urine blood to Hgb ratio (>=1);urine(protein,nitrite,mucus,leukocyte >=1 in urine dipstick test).
  • Fasting plasma glucose - change from baseline [ Time Frame: 84-days ]
  • Adverse events [ Time Frame: 84-days ]
  • Vitals - systolic blood pressure (SBP), diastolic blood pressue (DBP), heart rate [ Time Frame: 84-days ]
  • 12-lead electrocardiograms (ECGs) [ Time Frame: 84-days ]
  • Body weight [ Time Frame: 84-days ]
  • Clinical laboratory tests - hematology, chemistry, lipid profile, urinalysis [ Time Frame: 84-days ]
Not Provided
Not Provided
 
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety And Efficacy Of Pf-04937319 And Sitagliptin On Glycemic Control In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Type 2 Diabetes Mellitus
  • Drug: Placebo
    double-dummy placebo tablets administered once-daily for 84-days
  • Drug: PF-04937319 - 3mg
    PF-04937319 3mg administered as tablets once-daily for 84-days
  • Drug: PF-04937319 - 20mg
    PF-04937319 20mg administered as tablets once-daily for 84-days
  • Drug: PF-04937319 - 50mg
    PF-04937319 50mg administered as tablets once-daily for 84-days
  • Drug: PF-04937319 - 100mg
    PF-04937319 100mg administered as tablets once-daily for 84-days
  • Drug: Sitagliptin - 100mg
    Sitagliptin 100mg administered as tablets once-daily for 84-days
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Experimental: PF-04937319 - Dose 1
    Intervention: Drug: PF-04937319 - 3mg
  • Experimental: PF-04937319 - Dose 2
    Intervention: Drug: PF-04937319 - 20mg
  • Experimental: PF-04937319 - Dose 3
    Intervention: Drug: PF-04937319 - 50mg
  • Experimental: PF-04937319 - Dose 4
    Intervention: Drug: PF-04937319 - 100mg
  • Active Comparator: Sitagliptin
    Intervention: Drug: Sitagliptin - 100mg
Amin NB, Aggarwal N, Pall D, Paragh G, Denney WS, Le V, Riggs M, Calle RA. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9. doi: 10.1111/dom.12474.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
345
January 2013
January 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients with type 2 diabetes, on metformin, age between 18-55 yrs, male or female

Exclusion Criteria:

  • patients with type 1 diabetes, medically unstable, unacceptable clinical laboratory test results at screening
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States,   Hungary,   India,   Philippines,   Romania,   Slovakia,   South Africa,   Taiwan
 
 
NCT01475461
B1621007
2011-004002-25 ( EudraCT Number )
Yes
Not Provided
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP